Skip to main content
Top
Published in: Supportive Care in Cancer 10/2005

01-10-2005 | Editorial

Promoting science in a pragmatic world: not (yet) time for partial opioid rotation

Author: Florian Strasser

Published in: Supportive Care in Cancer | Issue 10/2005

Login to get access

Excerpt

For managing cancer pain, elaborated recommendations are available about the screening of pain intensity, the WHO ladder, a Cochrane review [22] and the European Association of Palliative Care (EAPC) recommendations of opioid analgesics [11], managing side effects of morphine (EAPC recommendations) [5] including opioid rotation [12], and stepwise approaches on how to integrate disease-directed treatments (radio- and chemotherapy) and neurolytic or neuraxial interventions [4]. However, we do not manage pain but rather assess, treat, and accompany patients [4] who suffer from various—often coexisting and fluctuating—pain syndromes [3], have risk factors for increased pain expression (incident or neuropathic pain, psychoexistential suffering, and a history of substance abuse) [7] requiring palliation of both pain and suffering [21], or need different interacting medications (even with restrictive nonpolypharmacy) for multidimensional symptom control. We also learned how to assess the impact of pain on patients’ function and involved family members, leading into the development of educational interventions [16]. With all these written and compassionately taught (best practice) recommendations, the majority of patients experience a satisfactory symptom control of pain syndromes, judged not only by pain intensity, but also by physical, social, and emotional function. …
Literature
1.
go back to reference Abbadie C, Pasternak GW (2001) Differential in vivo internalization of MOR-1 and MOR-1C by morphine. Neuroreport 12:3069–3072CrossRefPubMed Abbadie C, Pasternak GW (2001) Differential in vivo internalization of MOR-1 and MOR-1C by morphine. Neuroreport 12:3069–3072CrossRefPubMed
2.
go back to reference Bolan EA, Tallarida RJ, Pasternak GW (2002) Synergy between mu opioid ligands: evidence for functional interactions among mu opioid receptor subtypes. J Pharmacol Exp Ther 303:557–562CrossRefPubMed Bolan EA, Tallarida RJ, Pasternak GW (2002) Synergy between mu opioid ligands: evidence for functional interactions among mu opioid receptor subtypes. J Pharmacol Exp Ther 303:557–562CrossRefPubMed
3.
go back to reference Caraceni A, Portenoy RK (1999) An international survey of cancer pain characteristics and syndromes. IASP Task Force on Cancer Pain. International Association for the Study of Pain. Pain 82:263–274CrossRefPubMed Caraceni A, Portenoy RK (1999) An international survey of cancer pain characteristics and syndromes. IASP Task Force on Cancer Pain. International Association for the Study of Pain. Pain 82:263–274CrossRefPubMed
4.
5.
go back to reference Cherny N, Ripamonti C, Pereira J, Davis C, Fallon M, McQuay H, Mercadante S, Pasternak G, Ventafridda V, Expert Working Group of the European Association of Palliative Care Network (2001) Strategies to manage the adverse effects of oral morphine: an evidence-based report. J Clin Oncol 19:2542–2554PubMed Cherny N, Ripamonti C, Pereira J, Davis C, Fallon M, McQuay H, Mercadante S, Pasternak G, Ventafridda V, Expert Working Group of the European Association of Palliative Care Network (2001) Strategies to manage the adverse effects of oral morphine: an evidence-based report. J Clin Oncol 19:2542–2554PubMed
6.
go back to reference De Lima L, Sweeney C, Palmer JL, Bruera E (2004) Potent analgesics are more expensive for patients in developing countries: a comparative study. J Pain Palliat Care Pharmacother 18:59–70CrossRef De Lima L, Sweeney C, Palmer JL, Bruera E (2004) Potent analgesics are more expensive for patients in developing countries: a comparative study. J Pain Palliat Care Pharmacother 18:59–70CrossRef
7.
go back to reference Fainsinger RL, Nekolaichuk CL, Lawlor PG, Neumann CM, Hanson J, Vigano A (2005) A multicenter study of the revised Edmonton staging system for classifying cancer pain in advanced cancer patients. J Pain Symptom Manage 29:224–237CrossRefPubMed Fainsinger RL, Nekolaichuk CL, Lawlor PG, Neumann CM, Hanson J, Vigano A (2005) A multicenter study of the revised Edmonton staging system for classifying cancer pain in advanced cancer patients. J Pain Symptom Manage 29:224–237CrossRefPubMed
8.
go back to reference Gomes I, Gupta A, Filipovska J, Szeto HH, Pintar JE, Devi LA (2004) A role for heterodimerization of mu and delta opiate receptors in enhancing morphine analgesia. Proc Natl Acad Sci U S A 101:5135–5139CrossRefPubMed Gomes I, Gupta A, Filipovska J, Szeto HH, Pintar JE, Devi LA (2004) A role for heterodimerization of mu and delta opiate receptors in enhancing morphine analgesia. Proc Natl Acad Sci U S A 101:5135–5139CrossRefPubMed
9.
10.
go back to reference Grach M, Massalha W, Pud D, Adler R, Eisenberg E (2004) Can coadministration of oxycodone and morphine produce analgesic synergy in humans? An experimental cold pain study. Br J Clin Pharmacol 58:235–242CrossRefPubMed Grach M, Massalha W, Pud D, Adler R, Eisenberg E (2004) Can coadministration of oxycodone and morphine produce analgesic synergy in humans? An experimental cold pain study. Br J Clin Pharmacol 58:235–242CrossRefPubMed
11.
go back to reference Hanks GW, Conno F, Cherny N, Hanna M, Kalso E, McQuay HJ, Mercadante S, Meynadier J, Poulain P, Ripamonti C et al (2001) Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br J Cancer 84:587–593CrossRefPubMed Hanks GW, Conno F, Cherny N, Hanna M, Kalso E, McQuay HJ, Mercadante S, Meynadier J, Poulain P, Ripamonti C et al (2001) Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br J Cancer 84:587–593CrossRefPubMed
12.
go back to reference Indelicato RA, Portenoy RK (2002) Opioid rotation in the management of refractory cancer pain. J Clin Oncol 20:348–352PubMed Indelicato RA, Portenoy RK (2002) Opioid rotation in the management of refractory cancer pain. J Clin Oncol 20:348–352PubMed
13.
go back to reference Lauretti GR, Oliveira GM, Pereira NL (2003) Comparison of sustained-release morphine with sustained-release oxycodone in advanced cancer patients. Br J Cancer 89:2027–2030CrossRefPubMed Lauretti GR, Oliveira GM, Pereira NL (2003) Comparison of sustained-release morphine with sustained-release oxycodone in advanced cancer patients. Br J Cancer 89:2027–2030CrossRefPubMed
14.
go back to reference Mancini IL, Hanson J, Neumann CM, Bruera ED (2000) Opioid type and other clinical predictors of laxative dose in advanced cancer patients: a retrospective study. J Palliat Med 3:49–56CrossRefPubMed Mancini IL, Hanson J, Neumann CM, Bruera ED (2000) Opioid type and other clinical predictors of laxative dose in advanced cancer patients: a retrospective study. J Palliat Med 3:49–56CrossRefPubMed
15.
go back to reference Mercadante S, Villari P, Ferrera P, Casuccio A (2004) Addition of a second opioid may improve opioid response in cancer pain: preliminary data. Support Care Cancer 12:762–766CrossRefPubMed Mercadante S, Villari P, Ferrera P, Casuccio A (2004) Addition of a second opioid may improve opioid response in cancer pain: preliminary data. Support Care Cancer 12:762–766CrossRefPubMed
16.
go back to reference Miaskowski C, Dodd M, West C, Schumacher K, Paul SM, Tripathy D, Koo P (2004) Randomized clinical trial of the effectiveness of a self-care intervention to improve cancer pain management. J Clin Oncol 22:1713–1720CrossRefPubMed Miaskowski C, Dodd M, West C, Schumacher K, Paul SM, Tripathy D, Koo P (2004) Randomized clinical trial of the effectiveness of a self-care intervention to improve cancer pain management. J Clin Oncol 22:1713–1720CrossRefPubMed
17.
go back to reference Morita T, Tei Y, Inoue S (2003) Agitated terminal delirium and association with partial opioid substitution and hydration. J Palliat Med 6:557–563CrossRefPubMed Morita T, Tei Y, Inoue S (2003) Agitated terminal delirium and association with partial opioid substitution and hydration. J Palliat Med 6:557–563CrossRefPubMed
18.
go back to reference Nauck F, Ostgathe C, Klaschik E, Bausewein C, Fuchs M, Lindena G, Neuwohner K, Schulenberg D, Radbruch L, Working Group on the Core Documentation for Palliative Care Units in Germany (2004) Drugs in palliative care: results from a representative survey in Germany. Palliat Med 18:100–107CrossRefPubMed Nauck F, Ostgathe C, Klaschik E, Bausewein C, Fuchs M, Lindena G, Neuwohner K, Schulenberg D, Radbruch L, Working Group on the Core Documentation for Palliative Care Units in Germany (2004) Drugs in palliative care: results from a representative survey in Germany. Palliat Med 18:100–107CrossRefPubMed
19.
go back to reference Ross FB, Smith MT (1997) The intrinsic antinociceptive effects of oxycodone appear to be kappa-opioid receptor mediated. Pain 73:151–157CrossRefPubMed Ross FB, Smith MT (1997) The intrinsic antinociceptive effects of oxycodone appear to be kappa-opioid receptor mediated. Pain 73:151–157CrossRefPubMed
20.
go back to reference Strasser F (2003) Pathophysiology of anorexia/cachexia syndrome. In: Doyle D, Hanks G, Cherny N, Sir Calman K (eds). Oxford textbook of palliative medicine, 3rd edn. Oxford University Press, Oxford, pp 520–533 Strasser F (2003) Pathophysiology of anorexia/cachexia syndrome. In: Doyle D, Hanks G, Cherny N, Sir Calman K (eds). Oxford textbook of palliative medicine, 3rd edn. Oxford University Press, Oxford, pp 520–533
21.
go back to reference Strasser F, Walker P, Bruera E (2005) Palliative pain management: when both pain and suffering hurt. J Palliat Care 21(2):69–79 Strasser F, Walker P, Bruera E (2005) Palliative pain management: when both pain and suffering hurt. J Palliat Care 21(2):69–79
22.
go back to reference Wiffen PJ, Edwards JE, Barden J, McQuay HJ (2003) Oral morphine for cancer pain. Cochrane Database Syst Rev 4:CD003868PubMed Wiffen PJ, Edwards JE, Barden J, McQuay HJ (2003) Oral morphine for cancer pain. Cochrane Database Syst Rev 4:CD003868PubMed
Metadata
Title
Promoting science in a pragmatic world: not (yet) time for partial opioid rotation
Author
Florian Strasser
Publication date
01-10-2005
Publisher
Springer-Verlag
Published in
Supportive Care in Cancer / Issue 10/2005
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-005-0855-y

Other articles of this Issue 10/2005

Supportive Care in Cancer 10/2005 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine